31/03/2015 12:55:19 Free Membership Login

Neurocrine Biosciences News (NASDAQ:NBIX)

DateTimeSource
Headline
03/31/20156:31AMSEEKLet Neurocrine Biosciences Cool Off - Cramer's Lightning Round (3/30/15)
http://seekingalpha.com/article/3041016-let-neurocrine-biosciences-cool-off-cramers-lightning-round-3-30-15?source=partner_advfn More...>>
03/03/20151:00PMPRNUSNeurocrine Biosciences to Present at the Barclays Global Healthcare Conference Live Audio Webcast Will be on March 10, 2015
Neurocrine Biosciences to Present at the Barclays Global Healthcare Conference Live Audio Webcast Will be on March 10, 2015 PR Newswire SAN DIEGO, March 3, 2015 SAN DIEGO, March 3, 2015 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer... More...>>
02/24/20151:00PMPRNUSNeurocrine Biosciences to Present at Cowen and Company's 35th Annual Health Care Conference
Neurocrine Biosciences to Present at Cowen and Company's 35th Annual Health Care Conference Live Audio Webcast Will be on March 3, 2015 PR Newswire SAN DIEGO, Feb. 24, 2015 SAN DIEGO, Feb. 24, 2015 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive... More...>>
02/20/20157:00AMPRNUSNeurocrine Biosciences, Inc. Announces Exercise in Full of Underwriters' Option to Purchase Additional Shares
Neurocrine Biosciences, Inc. Announces Exercise in Full of Underwriters' Option to Purchase Additional Shares PR Newswire SAN DIEGO, Feb. 20, 2015 SAN DIEGO, Feb. 20, 2015 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that the underwriters of its previously announced public offering have exercised... More...>>
02/19/20157:00AMPRNUSNeurocrine Biosciences, Inc. Prices Public Offering of Common Stock
Neurocrine Biosciences, Inc. Prices Public Offering of Common Stock PR Newswire SAN DIEGO, Feb. 19, 2015 SAN DIEGO, Feb. 19, 2015 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the pricing of its underwritten public offering of 6,944,000 shares of its common stock at a price to the public of... More...>>
02/17/20154:08PMPRNUSNeurocrine Biosciences, Inc. Announces Proposed Public Offering of $225 Million of Common Stock
Neurocrine Biosciences, Inc. Announces Proposed Public Offering of $225 Million of Common Stock PR Newswire SAN DIEGO, Feb. 17, 2015 SAN DIEGO, Feb. 17, 2015 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it has commenced an underwritten public offering of shares of its common stock to... More...>>
02/09/20154:01PMPRNUSNeurocrine Biosciences Reports Year-End 2014 Results and Provides Investor Update for 2015
Neurocrine Biosciences Reports Year-End 2014 Results and Provides Investor Update for 2015 First Elagolix Phase III Study in Endometriosis is Successful Second Elagolix Phase III Study in Endometriosis Scheduled for Top-Line Readout in 2015 Phase IIb Elagolix Data for Uterine Fibroids in Second Half of 2015 NBI-98854 Phase... More...>>
02/04/20151:00PMPRNUSNeurocrine Biosciences to Present at the 2015 Leerink Global Healthcare Conference
Neurocrine Biosciences to Present at the 2015 Leerink Global Healthcare Conference Live Audio Webcast Will be on February 11, 2015 PR Newswire SAN DIEGO, Feb. 4, 2015 SAN DIEGO, Feb. 4, 2015 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Tim Coughlin, Chief Financial Officer of Neurocrine... More...>>
02/02/20151:00PMPRNUSNeurocrine Biosciences Announces Conference Call and Webcast to Report Fourth Quarter and Year-End 2014 Results
Neurocrine Biosciences Announces Conference Call and Webcast to Report Fourth Quarter and Year-End 2014 Results Conference Call and Webcast Scheduled For Monday, February 9, 2015 PR Newswire SAN DIEGO, Feb. 2, 2015 SAN DIEGO, Feb. 2, 2015 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that... More...>>
01/20/20158:00AMPRNUSNeurocrine Biosciences Announces Oral Presentation of NBI-77860 Clinical Trial Data in Classic Congenital Adrenal Hyperplasia...
Neurocrine Biosciences Announces Oral Presentation of NBI-77860 Clinical Trial Data in Classic Congenital Adrenal Hyperplasia at ENDO 2015 PR Newswire SAN DIEGO, Jan. 20, 2015 SAN DIEGO, Jan. 20, 2015 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that the steering committee of ENDO 2015 has... More...>>
01/16/20152:30PMPRNUSNeurocrine Biosciences Announces Granting of Orphan Drug Status for NBI-77860 in Congenital Adrenal Hyperplasia
Neurocrine Biosciences Announces Granting of Orphan Drug Status for NBI-77860 in Congenital Adrenal Hyperplasia PR Newswire SAN DIEGO, Jan. 16, 2015 SAN DIEGO, Jan. 16, 2015 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that NBI-77860, a proprietary corticotropin releasing factor 1 (CRF... More...>>
01/08/20151:00PMPRNUSNeurocrine Biosciences to Present at the 33rd Annual J.P. Morgan Healthcare Conference
Neurocrine Biosciences to Present at the 33rd Annual J.P. Morgan Healthcare Conference Live Audio Webcast will be on January 15, 2015 PR Newswire SAN DIEGO, Jan. 8, 2015 SAN DIEGO, Jan. 8, 2015 /PRNewswire/ --Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer... More...>>
01/08/20158:00AMPRNUSAbbVie Announces Positive Top-Line Results From Phase 3 Study of Investigational Medicine Elagolix in Patients with Endometri...
AbbVie Announces Positive Top-Line Results From Phase 3 Study of Investigational Medicine Elagolix in Patients with Endometriosis - Study meets co-primary efficacy endpoints; results show treatment with elagolix reduces endometriosis-associated pain (dysmenorrhea and non-menstrual pelvic pain) compared to placebo - Results... More...>>
12/10/20148:00AMPRNUSNeurocrine Biosciences Announces Expansion of its Clinical Pipeline
Neurocrine Biosciences Announces Expansion of its Clinical Pipeline Phase I/II Clinical Trial of CRF Antagonist in Adolescent Females with Classic Congenital Adrenal Hyperplasia Initial Pilot Clinical Study Demonstrated Profound Impact on Key Biomarkers PR Newswire SAN DIEGO, Dec. 10, 2014 SAN DIEGO, Dec. 10, 2014 /PRNewswire/... More...>>
12/04/20147:00PMPRNUSNeurocrine Biosciences to Present at the 25th Annual Oppenheimer Healthcare Conference
Neurocrine Biosciences to Present at the 25th Annual Oppenheimer Healthcare Conference Live Audio Webcast will be on December 10, 2014 PR Newswire SAN DIEGO, Dec. 4, 2014 SAN DIEGO, Dec. 4, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive... More...>>
11/25/20141:00PMPRNUSNeurocrine to Present at the 2014 Deutsche Bank BioFEST and the 26th Annual Piper Jaffray Healthcare Conference
Neurocrine to Present at the 2014 Deutsche Bank BioFEST and the 26th Annual Piper Jaffray Healthcare Conference Live Audio Webcasts will be on December 2nd and 3rd, 2014 PR Newswire SAN DIEGO, Nov. 25, 2014 SAN DIEGO, Nov. 25, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin... More...>>
11/12/20141:56PMPRNUSNeurocrine Biosciences to Present at the Jefferies 2014 Global Healthcare Conference
Neurocrine Biosciences to Present at the Jefferies 2014 Global Healthcare Conference Live Audio Webcast will be on November 19, 2014 PR Newswire SAN DIEGO, Nov. 12, 2014 SAN DIEGO, Nov. 12, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive... More...>>
11/12/20141:00PMPRNUSNeurocrine Biosciences to Present at the Jefferies 2014 Global Healthcare Conference
Neurocrine Biosciences to Present at the Jefferies 2014 Global Healthcare Conference Live Audio Webcast will be on November 19, 2014 PR Newswire SAN DIEGO, Nov. 12, 2014 SAN DIEGO, Nov. 12, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive... More...>>
11/04/20147:30AMPRNUSNeurocrine Biosciences, Inc. Announces Appointment of Darin Lippoldt as Chief Legal Officer
Neurocrine Biosciences, Inc. Announces Appointment of Darin Lippoldt as Chief Legal Officer PR Newswire SAN DIEGO, Nov. 4, 2014 SAN DIEGO, Nov. 4, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that Darin Lippoldt has joined the executive management team as Chief Legal Officer. "We are... More...>>
11/03/20147:00PMPRNUSNeurocrine Biosciences to Present at the Nomura Biotechnology Conference
Neurocrine Biosciences to Present at the Nomura Biotechnology Conference Live Audio Webcast will be on November 6, 2014 PR Newswire SAN DIEGO, Nov. 3, 2014 SAN DIEGO, Nov. 3, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine... More...>>


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE and AMEX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

1 site:2 us nasdaq nbix150331 12:55